Description
Femara (with letrozole generic formula) is an oral medication that is widely effective in fertility treatment mainly for ovulation problems or unexplained infertility. It belongs to the group of aromatase inhibitors. Femara also has an active role in the treatment of multiple breast cancer cases. Letrozole, in a form superior to Clomifen, can actively act on human female subjects who do not respond to Clomifen. Unlike clomiphene, Letrozole does not cause any unpleasant side effects if it can not be stopped.
Why it is used: Femara suppresses estrogen levels in young women as an effective aromatase inhibitor and consequently increases FSH (Follicle Stimulating Hormone) output from the pituitary gland and causes a mature follicle to develop in the ovary and ovum. Thus, in human females suffering from poliical over syndrome or anovulation (a problem with normal ovulation), ovulation or what the doctors call “ovulation induction” can trigger. Women who already soften themselves may benefit from the benefits of multiple follicles and multiple eggs during Femara’s treatment. This phenomenon can increase the chances of pregnancy compared to the release of a single egg during the natural menstrual cycle. This phenomenon is called superovulation in medical terminologies or controlled ovarian hypestimulation. Again, in intrauterine insemination (IUI) cases Femara has always played an important role in increasing the chances of pregnancy. Each year, women with ovarian complica- tions have approximately 15% healthy pregnancy chances, depending on factors such as the age of the patient, the condition of the fallopian tube, and the quality of the man’s sperm.
User Guidelines: Generally, Femara is administered at 2.5 mg / day for five days from menstrual cycle. Sometimes, higher doses of 5 mg or 7.5 mg per day may be used.
Side effects:
Incidence of higher birth defects despite under discussion
